£10m Cash Boost For UK Regulator To Speed Up New Drug Approvals
Tax Relief Move ‘A Huge Boost’ For Biotech
An injection of new money should provide something of a shot in the arm for the UK’s drugs regulator as it deals with post-Brexit realities.
You may also be interested in...
UK’s Revamped Clinical Trials Framework To Offer Faster Application Review Timelines Than EU
The UK has finalized plans for delivering what it believes will be a stable and streamlined clinical trials framework following its departure from the EU. Transparency, patient involvement and diversity are high on the agenda.
ABPI’s 6.88% Rebate Proposal ‘Completely Unaffordable,’ Says UK Health Dept
Plans for a new kind of drug pricing scheme put forward by the UK ABPI are intended to put the life sciences sector “back on the path for future growth,” the association says.
UK Prepares For New International Regulatory Reliance Framework
From next year, more agencies will be involved in the UK’s regulatory reliance procedure for new drug approvals, which was first introduced in 2021 to allay fears of post-Brexit delays to UK applications. The pharmaceutical industry said it looked forward to working with the regulator on the new framework.